In an effort to find additional compounds that could be beneficial in SCN8A-associated epilepsy, Atkin et al., conducted an in vitro screen of 1,320 pharmaceutical compounds to identify those that reduce sodium influx into HEK293 cells transfected with constructs expressing either wild-type SCN8A or the SCN8A R1872Q mutation. The gene discussed is SCN8A; the disease is epilepsy.